ArticleFrontiers in immunology2025
Risk factors and a new nomogram for glioblastoma: based on a retrospective study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma (GBM) is the most common and aggressive primary malignant tumor of the adult central nervous system. Despite multimodal therapy, its prognosis remains poor, with a median overall survival of 14-16 months. While rare genetic syndromes and prior cranial irradiation have been implicated, definitive environmental or biological risk factors for GBM remain elusive. Methods: In this retrospective study, we analyzed data from 94 patients with pathologically confirmed GBM and 94 matched non-tumor controls treated at Guangdong Academy of Medical Sciences between 2016 and 2023. Univariate and multivariate logistic regression analyses were conducted to identify independent risk factors, which were subsequently used to construct a predictive nomogram. Model performance was assessed using concordance index (C-index), receiver operating characteristic (ROC) curves, and calibration plots in both training and validation cohorts. Results: Six independent risk factors were identified: serum chloride (Cl), magnesium (Mg), high-density lipoprotein cholesterol (HDL-C), uric acid (UA), eosinophil count, and basophil count. A novel nomogram incorporating these factors demonstrated strong predictive ability, with a C-index of 0.871. Conclusions: We present a validated, blood-based nomogram for GBM risk prediction with high discriminative power. This model may aid clinicians in early identification and personalized management of high-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.